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Introduction: There is controversy regarding the role of yttrium-90 (90Y) radioembolization in the
management of advanced, unresectable hepatocellular carcinoma (HCC). Methods: Forty-ﬁve consecu-
tive patients underwent resin-based 90Y radioembolization for unresectable, HCC between 2006 and
2013 in Sydney, Australia. All patients were followed up with imaging studies at regular intervals until
death. Radiologic response was evaluated with the Response Criteria in Solid Tumors (RECIST) criteria.
Clinical toxicities were prospectively recorded. Survival was calculated by the KaplaneMeier method and
potential prognostic variables were identiﬁed on univariate and multivariate analysis. Results: Follow-up
in the complete cohort was 7.8 (range, 0.1e41.8) months. The median survival after 90Y radio-
embolization was 27.7 months with a 36-month survival of 26%. By RECIST criteria of the 40 patients
followed-up beyond 2 months, a complete response (CR) to treatment was observed in 1 patients (3%),
partial response (PR) in 18 (45%), stable disease (SD) in 11 (22%) and progressive disease (PD) in 10 (25%).
On multivariate analysis only radiological response to treatment was independently associated with
improved survival: CR/PR to treatment vs. SD vs. PD; p < 0.001. Thirteen patients (29%) developed clinical
toxicity after treatment; all complications were minor (grade I/II) and resolved without active inter-
vention. Conclusion: Radioembolization with 90Y is a safe and effective treatment for unresectable HCC.
© 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
Hepatocellular carcinoma (HCC) is the most common primary
hepatic malignancy accounting for an estimated 70e85% of theonal Radiology, St Vincent's
a).
f of Surgical Associates Ltd.748,000 cases diagnosed worldwide [1]. This disease is endemic
in sub-Saharan Africa and South East Asia; however, recent
epidemiological data has demonstrated an increased incidence in
developed countries worldwide [1,2].
Without early detection and aggressive treatment, HCC is
invariably fatal. Patients with advanced HCC managed with best
supportive care have a median survival of around 6 months [3,4].
The only potentially curative treatment options are surgical
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judicious patient selection is imperative and 5-year survival from
high-volume institutions varies between 40 and 85% [3,5,6]. Un-
fortunately, however, HCC is most frequently diagnosed at an in-
termediate or advanced stage when curative surgical strategies are
not possible [3]. HCC is chemoresistant and a signiﬁcant proportion
of patients have poor liver reserve secondary to pre-existing
cirrhosis and/or compromised portal vein ﬂow; consequently,
unresectable HCC portends a poor prognosis [3,7].
Nevertheless, signiﬁcant efforts have been expended by the
oncology community towards ﬁnding an effective treatment for
unresectable HCC. There is randomized evidence suggesting that
locoregional treatment with transarterial chemoembolization
(TACE) is superior to symptomatic treatment in patients with in-
termediate stage HCC; indeed, both the American Association for
the Study of Liver Diseases (AASLD) and the European Organization
for Research and Treatment of Cancer (EORTC) recommend TACE
for the management of unresectable intermediate-stage HCC
[3,8e10]. Patient with decompensated liver disease or advanced
liver dysfunction secondary to cirrhosis, however, have a poor
tolerance for TACE [3,11,12]. In recent years, transarterial radio-
embolization using yttrium-90 (90Y) microspheres has been pro-
posed as an alternative treatment to TACE. Several studies have
shown that 90Y radioembolization is safe, with a lower incidence of
embolic complications such as fever and abdominal pain, compared
with TACE [12e14]. 90Y radioembolization is an approved treat-
ment for patients with HCC and portal vein thrombosis (PVT);
conversely, PVT is a relative contraindication for TACE due to the
risk of ischemic hepatitis [15]. Moreover, 90Y radioembolization
has been shown to be efﬁcacious with comparable tumor response
and survival rates to TACE [15e17]. Unfortunately, the widespread
adoption of 90Y radioembolization has been precluded by a relative
lack of quality clinical data. The aim of this study was to report our
Australian experience on the safety and efﬁcacy of 90Y radio-
embolization for unresectable HCC. As a secondary objective,
prognostic factors for overall survival after 90Y radioembolization
were identiﬁed.
2. Methods
This retrospective study was approved by a local institutional
review board. Informed consent was obtained from all patients.
Forty-ﬁve consecutive patients with HCC were treated by selective
internal radiation therapy with 90Y microspheres (SIR-spheres,
Sirtex Medical, Sydney, Australia) between May 2006 and
September 2012. Inclusion criteria were as follows: (a) radiologi-
cally proven hepatocellular carcinoma not amenable to curative
surgical resection; (b) aged 18e85 years; (c) ability to undergo
angiography and selective visceral catheterization; (d) Eastern
Cooperative Oncology Group (ECOG) performance status of 0e2
and (e) adequate hematology (granulocyte count  1.5  109/L,
platelets 50109/L), renal function (creatinine level 2.0mg/dL)
and hepatic function (bilirubin level  2.0 mg/dL). Patients with
limited extra-hepatic disease not deemed clinically important were
not excluded.
Prior to 90Y treatment, patients underwent routine baseline
serology including liver function tests and computerized tomog-
raphy (CT) imaging scans of the liver. In addition, each patient
underwent a liver angiography with 99m technetium-labeled
macroaggregated albumin (99mTc-MAA) scintigraph to identify
any aberrant hepatic anatomy and percentage of lung shunting.
Temporary balloon occlusion was performed if arteriovenous lung
shunting was >20% on 99mTc-MAA to reduce the risk of pneumo-
nitis [18]. In brief, temporary occlusion of shunts was achieved by
placement of balloon catheters in the hepatic veins. Thisendovascular technique reduces arteriohepatovenous shunting and
allows otherwise untreatable patients to undergo radio-
embolization. The total volume of the liver and the volume of the
right and left lobes were calculated using preoperative CT scans.
Similarly, the total percentage of liver replacement by tumor and
the percentage replacement in the right and left lobes were
calculated using preoperative CT scans. Activity of 90Y treatment
was measured in gigabecquerels (GBq) and adjusted to tumor
volume and lung shunting fraction. Dosages were calculated ac-
cording to patient surface area, as previously described [19].
A standard dose of 90Y radioactivity contains approximately
50 million resin microspheres measuring 29e35 mm each and
provides 2 GBq. 90Y is a pure b emitter with a half-life of 64.2 h
and decays into stable zirconium-90. The beta emission of 90Y
has a mean tissue penetration of 2.5 mm (maximum of 10 mm)
and has an average energy emission of 0.937 MeV. The micro-
spheres were injected through a temporary hepatic artery
catheter placed percutaneously through the femoral or brachial
artery. Unless contraindicated, treatment for bilobar liver disease
was performed in the same procedure, with a measured fraction
of microspheres ﬁrstly injected into the right hepatic artery,
followed by partial withdrawal and repositioning of the catheter
into the left hepatic artery to allow the remaining microspheres
to be infused. In the majority of patients, approximately two-
thirds of microspheres were injected into the right hepatic ar-
tery and one-third into the left hepatic artery. In patients who
had disease primarily conﬁned to one lobe, dose distribution was
adjusted accordingly.
Following treatment, all patients were hospitalized overnight as
per the departmental protocol. The aim of this was to optimize
patient management in the instance of a post-radioembolization
adverse event. Patients were initially followed up after one
month and then at 3-month intervals until death. Blood,
biochemical and tumor markers in addition to abdominal CT scans
were obtained and assessed at each follow up visit.
The primary outcome of this study was overall survival and
radiological hepatic tumor response. Radiological response was
assessed by an experienced radiologist in accordance with the
Response Criteria in Solid Tumors (RECIST) guidelines by compar-
ison of each follow up examination with the baseline examination
[20]. In brief, a complete response (CR) is deﬁned as disappearance
of lesions; partial response (PR), as a 30% decrease in the sum of
the longest diameter of the index lesions; stable disease (SD), as a
<30% decrease or <20% increase in the sum of the longest diameter
of the index lesions; and progressive disease (PD), as a 20% in-
crease in the sum of the longest diameter of the index lesions or
appearance of new lesions. Secondary outcomes included treat-
ment safety and prognostic factors for overall survival and treat-
ment response. We prospectively collected and reviewed patient
clinicopathologic and treatment related data.2.1. Statistical analysis
Clinicopathological and treatment-related variables were
analyzed for an association with a treatment response (complete/
partial response or stable disease) and overall survival. Categorical
variables were compared using Chi2 analysis or Fisher's exact test
where appropriate. Survival analysis was performed by using
KaplaneMeier method and compared using the log-rank test. To
assess the variation in each liver function test over the previous
follow up, we used the one-way analysis of variance. All statistical
analyses were performed using the Statistical Package for Social
Sciences for Windows (Version 17.5; SPSS GmbH, Munich Ger-
many). A signiﬁcant difference was deﬁned as p < 0.05.
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3.1. Patient characteristics
A total of 45 patients with HCC underwent treatment with 90Y
microspheres between May 2006 and July 2013. A summary of
patient clinicopathological and treatment-related variables is pro-
vided in Table 1. There were 37 (82%) males. The mean age of pa-
tients at the time of treatment was 63.6 ± 11.3 years (range, 37e85).
The majority of patients presented with bilobar disease (n ¼ 31,
69%). The Eastern Cooperative Oncology Group (ECOG) perfor-
mance status was 0 in 30 patients (67%),1 in 12 patients (27%) and 2
in 3 patients (7%). Child-Pugh status was A (5e6) in 30 patients
(67%), B (7e9) in 10 patients (22%), C (10e15) in 1 patient (2%) and
unknown in 4 patients (9%). Sixteen patients (36%) had 26%
replacement of the liver by tumor.Table 1
A summary of clinicopathological and treatment-related factors of 40 patients with
BRCLM who underwent 90Y radioembolization.
Clinicopathological and treatment-related factors Number of
patients
Total 45
Sex e
Male 37
Female 8
Age at time of resection (years) e
Mean (±S.D.) 63.6 ± 11.3
<64 19
64 26
Replacement of liver by tumor (%) e
0e25 29
26e50 15
51e75 1
Extent of hepatic disease e
Bilobar 31
Unilobar 14
Eastern Cooperative Oncology Group (ECOG) status e
0 30
1 12
2 3
Previous hepatic resection e
Yes 6
No 39
Previous transarterial chemoembolization/
hepatic artery chemoinfusion
e
Yes 11
No 34
Number of previous lines of chemotherapy e
0 39
1e2 6
Child-Pugh Status e
A (5e6) 30
B (7e9) 10
C (10e15) 1
Unknown 4
Extra-hepatic disease e
Yes 5
No 40
Radioembolization activity (Gbq) e
Mean (±S.D.) 1.49 ± 0.56
Range 0.34e2.50
Lung shunting (%) e
Mean (±S.D.) 6.0 ± 4.8
Range 1.4e26.0
Pre-operative blood parameters e
Bilirubin (Mean ± S.D.) 18.5 ± 13.3
Albumin (Mean ± S.D.) 36.5 ± 6.1
Aspartate transaminase (AST) (Mean ± S.D.) 81.3 ± 55.6
Alanine aminotransferase (ALT) (Mean ± S.D.) 61.0 ± 38.7
Hemoglobin (Hb) (Mean ± S.D.) 129.8 ± 18.0
Platelet (Plt) (Mean ± S.D.) 182.9 ± 133.4
Creatinine (Cr) (Mean ± S.D.) 75.9 ± 20.2At study entry, 5 patients (11%) had histologic or documented CT
evidence of limited extra-hepatic disease. Six patients (13%) had
previously undergone a liver resection. Eleven (24%) patients had
previously undergone transarterial chemoembolization or hepatic
artery chemoinfusion; four patients (9%) had previously undergone
ablative therapy. Six patients (13%) had been previously treated
with at least one line of systemic chemotherapy.
The mean dose of 90Y was 1.49 GBq (S.D. ¼ 0.56; range,
0.34e2.50), and the estimated percentage shunting to the lungs
was 6.0% (S.D. ¼ 4.8; range, 1.4e26.0%). Fifteen (33%) patients
required embolization of non-hepatic arteries to prevent non-
targeted ﬂow.
3.2. Clinical toxicity
No patient died as a result of treatment. A total of 13 (29%) pa-
tients developed clinical toxicity after treatment. Clinical toxicities
included nausea/vomiting in 6 patients (13%); fatigue in 6 patients
(13%), non-speciﬁc self-limiting abdominal pain in 4 patients (9%);
anorexia in 3 patients (7%); and shortness of breath in 1 patient
(3%). These complications were minor (Grade I/II) and resolved
without active intervention. Post-procedural imaging ﬁndings
demonstrated ascites and pleural effusion and in 2 patients (4%)
each, respectively.
3.3. Treatment response
Forty patients (89%) were followed up beyond 2 month after
initial radioembolization therapy and underwent follow-up CT
imaging from which hepatic tumor response was assessed in
accordance with RECIST criteria. Overall, a complete response to
treatment was observed in 1 patients (of 40, 3%), partial response to
treatment was observed in 18 patients (45%), stable disease in 11
patients (22%), and progressive disease in 10 patients (25%).
3.4. Overall survival
The median follow-up period for all patients after 90Y radio-
embolization was 7.8 months (range, 0.1e41.8 months), with none
lost to follow-up. The median survival after the ﬁrst treatment with
90Y radioembolizationwas 27.7 months with 6-month and 12-, 18-,
24-, 30-, and 36-month survival of 74%, 62%, 50%, 50%, 43% and 26%,
respectively (Fig. 1).
Univariate analysis identiﬁed six factors associated with overall
survival: Extent of replacement of hepatic parenchyma by tumor
(<25% vs. 26e50% vs. 51%, p ¼ 0.016), ECOG status (0 vs. 1;
p ¼ 0.003), number of previous lines of chemotherapy (0 vs. 1e2;
p ¼ 0.033), Child Pugh status (A vs. B/C; p ¼ 0.006), radiological
response to treatment (CR/PR vs. SD vs. PD, p < 0.001) and pre-
operative bilirubin (<19 vs. 19; p ¼ 0.012). Table 2 demonstrates
the signiﬁcance of clinicopathological and treatment-related
prognostic factors for overall survival.
On multivariate analysis, a poor radiological response to treat-
ment (HR, 24.17; 95% Conﬁdence Interval (CI), 5.37e108.86;
p < 0.001) (Fig. 2) was associated with a poorer prognosis. Fig. 3
shows the association of Child-Pugh status with overall survival.
4. Discussion
Our study demonstrated that 90Y radioembolization of 45 pa-
tients with unresectable HCC resulted in a median survival of 27.7
months with a 3-year survival of 26%. These data, in the context of
what is otherwise a fatal disease, are excellent. Patients with
advanced HCC managed with best supportive care generally have a
median survival of less than 6 months with a 3-year survival of
Table 2
Association of clinicopathological and treatment-related factors with overall sur-
vival on univariate analysis.
Clinicopathological and
treatment-related factors
Number of
patients
Median
survival
(months)
P value
Total 45 e
Age at time of resection (years) e e 0.172
<64 19 12.8 e
64 26 27.7 e
Replacement of liver by tumor (%) e e 0.016
0e25 29 27.7 e
26e50 15 4.8 e
51e75 1 3.0 e
Extent of hepatic disease e e 0.262
Bilobar 31 15.6 e
Unilobar 14 35.0 e
Eastern Cooperative Oncology
Group (ECOG) status
e e 0.003
0 30 30.8 e
1 15 4.8 e
Extra-hepatic disease e e 0.718
Yes 5 27.7 e
No 40 15.9 e
Previous hepatic resection e 0.902
Yes 6 15.9 e
No 39 27.7 e
Number of previous lines of chemotherapy e e 0.033
0 39 27.7 e
1e2 6 3.5 e
Previous transarterial chemoembolization/
hepatic artery chemoinfusion
e e 0.700
Yes 11 7.8 e
No 34 27.7 e
Child Pugh Status e e 0.006
A (5e6) 30 30.8 e
B (7e9) or C (10e15) 11 3.3 e
Radiological response e e <0.001
Complete response/Partial response 19 35.0 e
Stable disease 11 10.5 e
Progressive disease 10 3.0 e
Aspartate transaminase (AST) e e 0.949
<81 25 27.7 e
81 17 NR e
Alanine aminotransferase (ALT) e e 0.774
<61 26 30.9 e
61 17 27.7 e
Hemoglobin (Hb) e e 0.887
<129 22 12.8 e
129 21 27.7 e
Creatinine (Cr) e e 0.389
<76 23 30.8 e
76 20 15.9 e
Bilirubin (Bi) e e 0.012
<19 28 30.8 e
19 15 4.8 e
Fig. 1. Overall survival of 45 patients with HCC who underwent 90Y
radioembolization.
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presented with features of advanced disease including high tumor
burden, extra-hepatic disease, advanced cirrhosis, and impaired
performance status. Our encouraging ﬁndings are commensurate
with those reported in earlier series. Moreno-Luna and colleagues
[12], from theMayo clinic, in a series of 62 patients who underwent
glass-based 90Y radioembolization for HCC, reported a median
survival of 15.0 months with a 2-year survival of 30%. Salem and
colleagues [15] reported on 123 patients who underwent glass-
based radioembolization; median survival in this cohort was 20.5
months with a 2- and 3-year survival of 46% and 25%, respectively.
Mazzaferro and colleagues [21] analyzed 52 patients with
intermediate-advanced HCC treated with resin-based micro-
spheres and demonstrated a median survival of 15.0 months with a
2-year survival of 30%. Collectively, these data demonstrate that
90Y radioembolization is an effective treatment for patients with
advanced, unresectable HCC.
HCC is among themost chemo-resistant tumor types; until 2007
no systemic drug was recommended [3]. Sorafenib has since
emerged as the ﬁrst effective systemic treatment for HCC. Llovet
and colleagues [22] performed a multicenter, phase III, double-
blind, placebo-controlled trial on patients with advanced HCC
who were randomized to receive either sorafenib or placebo. The
authors demonstrated a median survival of 10.7 months in the
sorafenib group compared to 7.9 months in the placebo group. This
was signiﬁcant (hazard ratio (HR), 0.69; 95% conﬁdence interval
(CI), 0.55e0.87; p < 0.001). Sorafenib, however, only induced an
objective radiological response in 2% of patients; in contrast, we
observed an objective response (CR/PR) rate of 48%. Similar results
have been reported with RECIST CR/PR response ranging from 35 to
50% in patients who have undergone 90Y radioembolization
[3,12,14,15,21]. These data underlie the role of 90Y radio-
embolization in the management of unresectable HCC, rather than
systemic agents, whenever possible.
On multivariate analysis, objective response (CR/PR) was the
only factor associated with improved survival (p < 0.001). This
ﬁnding is not unexpected and has been reported before [21,23].
Mazzaferro and colleagues [21] showed that radiological response
(CR/PR/SD vs. PD) was an independent risk factor for both poorer
overall survival (p ¼ 0.048) and time to progression (p ¼ 0.0001).The authors also demonstrated that Child Pugh classiﬁcation was
an independent prognostic factor; mortality rate in patients with
Child B disease was more than triple that in patients with Child A
disease (HR, 3.66; 95% CI, 1.56e8.58; p ¼ 0.0028). In our series,
median survival was signiﬁcantly superior, on univariate analysis,
in patients with Child A disease compared to those with Child B/C
disease (30.8 vs. 3.3 months, p ¼ 0.006). Whilst Child-Pugh score
was not prognostic on multivariate analysis, this may have been
because the current study was insufﬁciently powered to detect an
actual difference. Hilgard and colleagues [14] in an analysis of 108
patients who underwent glass-based 90Y radioembolization also
demonstratedmarkedly improvedmedian survival in patients with
Child A disease (17.2 vs. 6 months; p ¼ 0.013). Collectively, these
studies have shown that survival outcomes in patients with Child B/
C disease are uniformly poor. It is imperative, therefore, for clini-
cians to thoroughly evaluate the suitability of these patients for 90Y
Fig. 2. Overall survival, stratiﬁed by radiological response.
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tients with extensive hepatic replacement by tumor and a subop-
timal performance status had worse outcomes. Interestingly,
patients who previously had undergone systemic treatment had a
poorer prognosis, perhaps reﬂecting more aggressive and advanced
disease at the time of 90Y radioembolization. Limited extra-hepatic
disease did not compromise survival outcomes in this study.
The current recommended ﬁrst-line therapy for patients with
intermediate HCC is transarterial chemoembolization (TACE) [3,9].
HCC exhibits intense neo-angiogenic activity during its progres-
sion. The rationale for TACE is that the intra-arterial infusion of a
cytotoxic agent followed by embolization of the tumor feeding
blood vessels will results in a strong cytotoxic and ischemic effect.
Chemoembolization achieves an objective response in 15e55% ofFig. 3. Overall survival, stratiﬁed by Child-Pugh classiﬁcation.patients and signiﬁcantly delays tumor progression and macro-
vascular invasion [3]. There is randomized evidence to support its
efﬁcacy compared to supportive therapy [8,10]. Median survival has
been reported around 20 months in most series, ranging from 14 to
45 months [3,8,10].
A distinct disadvantage of chemoembolization is that the mac-
roembolic effect and arterial occlusion it entails triggers a cascade
of events including overexpression of vascular endothelial growth
factor and hypoxia inducible factor 1 [15,24,25]. Clinically, this
manifests as pain and post-embolization syndrome, often requiring
hospitalization. Moreover, permanent occlusion of hepatic vessels
is possible. In contrast, 90Y radioembolization exerts a micro-
embolic effect without arterial occlusion [26]. Hence, there is no
hypoxia-initiated cascade; clinical sequelae are derived from radi-
ation and include post-radioembolization syndrome, dominated by
fatigue managed without hospitalization [15]. In addition, chemo-
embolization is relatively contraindicated in patients with portal
vein thrombosis because of the profound ischemic effect it exerts
[9]. In the presence of PVT, the hepatic artery may be the only
supply of blood to the liver; hence, a microembolic therapy such as
90Y radioembolization provides a new therapeutic option for pa-
tients with compromised portal ﬂow [9,15].
Several studies have compared the relative efﬁcacy of radio-
embolization and chemoembolization; all have shown that radio-
embolization is as effective, if not more effective, in inducing a
radiological response and improving survival, as chemo-
embolization [12,15e17]. Salem and colleagues [15] compared the
outcomes of 122 patients who underwent 90Y radioembolization
with 123 patients treated with chemoembolization. Complications,
in particular abdominal pain and liver dysfunction were more
common following chemoembolization (p < 0.05). A trends to-
wards higher objective response rate (49% vs. 36%, p ¼ 0.104) was
observed in patients undergoing radioembolization. Time-to-
progression was longer following radioembolization (13.3 months
vs. 8.4 months, p ¼ 0.046) but median survival times were not
statistically difference (20.5months vs.17.4 months, p¼ 0.232). The
same authors subsequently demonstrated that quality of life out-
comes were better in patients undergoing radioembolization,
rather than chemoembolization, despite the fact more patients
presented with advanced disease [27].
Similar to chemoembolization, 90Y radioembolization may
“downstage” a signiﬁcant proportion of patients who initially
presented with unresectable HCC so that they may undergo
potentially curative radical treatments [28,29]. I~narrairaegui and
colleagues [29] reported that of 118 patients with unresectable HCC
who underwent 90Y radioembolization, 21 (18%) were downstaged
and treated radically between 2 and 35 months post-
radioembolization. Interestingly, patients who were treated radi-
cally initially presented with a higher tumor volume (583 mL vs.
137 mL, p ¼ 0.001). Across the whole series, median survival was
27.0 months, varying signiﬁcantly between those treated radically
(median survival not reached) and those who received palliative
treatment only (median survival ¼ 22 months). Unfortunately, the
widespread adoption of 90Y radioembolization and the continued
reliance on TACE for the management of unresectable HCC reﬂects
the lack of quality, randomized data. This represents an important
avenue of research for future studies.
90Y radioembolization is safe; clinical toxicity was low in the
current study at 29% and all events were self-limiting which
resolved without active intervention. As per previous studies, fa-
tigue, abdominal pain and nausea/vomiting were themost frequent
complication. In our series, there was no treatment-related mor-
tality or serious complications such as decompensated liver disease
or gastrointestinal ulceration, although they have been infre-
quently reported [30].
A. Saxena et al. / International Journal of Surgery 12 (2014) 1403e14081408In conclusion, 90Y radioembolization is a safe and effective
treatment for advanced, unresectable HCC. In the current series, the
clinical toxicity rate was low (29%) and objective response rates
were high (48%). Moreover, median overall survival at 27.7 months
was excellent in a group of patients with advanced disease. Further
prospective, randomized investigation comparing this treatment to
the current standard of care, TACE, is necessary to determine its role
in the management of unresectable HCC.
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